Save

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

PHASE1PHASE2RECRUITING

Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 in patients with recurrent advanced/metastatic cancer, including hormone receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) regimen, and CCNE1-amplified solid tumors who progressed on standard of care treatment. This study will evaluate approximately 6 dose levels of daily INX-315 in Part A, at least two dose levels will be evaluated in Part B to identify the Recommended Phase 2 Dose (RP2D) in patients with ovarian cancer, and Part C will evaluate combination treatment of INX-315 plus a CDK4/6i and selective estrogen receptor degrader (SERD) in HR+/HER2- breast cancer patients who have progressed on prior CDK4/6i regimen.

Simpliy with AI

Study details:

Study INX-315-01 is a first-in-human, Phase 1/2, open-label, dose escalation and dose-expansion study to evaluate the safety, PK, and preliminary antitumor activity of INX-315 in patients with advanced/metastatic cancers. The study will be conducted in 3 parts: Part A (dose escalation) and Part B (ovarian cancer dose expansion) and Part C (breast cancer dose escalation lead-in and expansion). Part A is the dose-escalation portion of the study to evaluate the safety, tolerability, and PK of INX-315 monotherapy.

Dosing decisions will be guided using a Bayesian optimal interval (BOIN) design. Up to 60 patients with recurrent advanced/metastatic cancer, including patients with HR+/HER2- breast cancer who progressed on a prior CDK4/6i regimen, and solid tumors, including ovarian cancer with known amplification of CCNE1 are planned to be enrolled in Part A. Dose-limiting toxicities (DLTs) will be assessed during the first treatment cycle, i.

e. , the first 28 days of treatment (the DLT period). Patients who are evaluable for DLT assessment are those patients who are enrolled, received ≥80% of the planned study drug doses and all study visits during the DLT assessment period, and complete the 28-day DLT period.

Additionally, Part A will have two cohorts that will include INX-315 plus fulvestrant in HR+/HER2- patients who have have had prior treatment with CDK4/6i. Part B will expand at least two dose levels determined by the SMC. Part B will enroll patients with platinum-refractory or platinum-resistant advanced/metastatic ovarian cancer patients with CCNE1 amplifications.

Part B will open for enrollment once the SMC has selected the dose levels to be evaluated from the Part A portion of the study. Part A patients cannot re-join or continue the study in Part B. Approximately 30 patients will be equally randomized to receive one of the dose levels of INX-315.

Part C will be an expansion cohort, patients with ER+/HER2- breast cancer will be enrolled in this cohort.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Advanced unresectable or metastatic ER+/HER2- BC that has progressed following treatment with a CDK4/6 inhibitor

Advanced/ metastatic platinum-resistant or platinum-refractory epithelial ovarian cancer (including fallopian tube cancer/primary peritoneal cancer) CCNE1 amplified tumors that progressed after standard systemic therapy

Advanced or metastatic solid tumor with known amplification of CCNE1 that has progressed after standard therapy, been intolerant to or is ineligible for standard therapy

At least one measurable lesion as defined by RECIST v1.1 that has not previously been irradiated

ECOG performance status score of 0 or 1.

Adequate organ function as demonstrated by the following laboratory values: Hemoglobin ≥ 9.0 g/dL, Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L, Platelet count ≥ 100 × 10^9/L, Estimated glomerular filtration rate (eGFR) of ≥60 mL/min, Total bilirubin ≤ 1.5 × ULN; AST and ALT ≤ 2.5 × ULN; ≤ 5 × ULN in the presence of liver metastases

Negative pregnancy test

Exclusion criteria

Have received previous therapy with a CDK2/4/6 inhibitor or CDK2 inhibitor.

Have central nervous system (CNS) metastases or spinal cord compression that is associated with progressive neurological symptoms or requires corticosteroids (within 4 weeks of enrollment) to control the CNS disease.

Have known intracranial hemorrhage and/or bleeding diatheses.

Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis.

Have clinically active ongoing interstitial lung disease (ILD) of any etiology, including drug-induced ILD, and radiation pneumonitis within 28 days prior to initiation of study treatment.

Resting QTcF > 470 msec, a history of prolonged QT syndrome or Torsades de pointes, or a familial history of prolonged QT syndrome.

Uncontrolled, cardiovascular disease (including hypertension) with or without medication

History of other malignancies, except for the following: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated a) in situ carcinoma of the uterine cervix, b) prostate cancer, or c) superficial bladder cancer; or (3) other curatively treated solid tumor with no evidence of disease for ≥ 3 years.

Known HIV infection, including AIDS-related illness, or have active, uncontrolled infection (viral, bacterial, or fungal), including tuberculosis, hepatitis B virus, hepatitis C virus, or COVID-19 infection (symptoms and a positive test result).

Requires treatment with a prohibited medication or herbal remedy that cannot be discontinued at least 2 weeks before the start of study drug administration.

Have planned or anticipation of the need for major surgical procedure within 28 days of the first dose of study drug (procedures such as central venous catheter placement, tumor needle biopsy, and feeding tube placement are not considered major surgical procedures).

Unwilling or unable to comply with scheduled visits, study drug administration plan, laboratory tests, or other study procedures and study restrictions.

Radical radiotherapy within 28 days prior to study entry or palliative radiotherapy within 2 weeks prior to study entry.

Systemic anti-cancer therapy within 28 days or at least 5 half-lives, whichever is less, prior to the first dose of the study drug

Prior irradiation to > 25% of the bone marrow

Previous high-dose chemotherapy requiring prior stem cell transplant

Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry.

Known or suspected hypersensitivity to active ingredient/excipients in INX-315 or fulvestrant.

Known difficulty in swallowing or tolerating oral medications, or conditions which would impair absorption of oral medications such as active inflammatory gastrointestinal disease, uncontrolled nausea or vomiting (i.e., CTCAE ≥ Grade 3 despite antiemetic therapy), ongoing gastrointestinal obstruction/motility disorder/active inflammation, malabsorption syndrome, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2023-03-28

Primary completion: 2025-12-01

Study completion finish: 2026-06-01

Study type

TREATMENT

Phase

PHASE1

PHASE2

Trial ID

NCT05735080

Intervention or treatment

DRUG: INX-315

DRUG: Fulvestrant

Conditions

• Breast Cancer
• Hormone Receptor Positive Tumor
• Ovarian Cancer
• Solid Tumor
• Advanced Cancer
• Breast Cancer Metastatic
• Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
• CCNE1 Amplification
• Metastatic Cancer

Condition: Breast Cancer, Hormone Receptor Positive Tumor and more
DRUG: INX-315 and other drugs
Parkville, Victoria, Australia and more
Sponsor: Incyclix Bio

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Peter MacCallum Cancer Center

Research sites nearby

Select from list below to view details:

Peter MacCallum Cancer Center
Parkville, Victoria, Australia
Mater Hospital
South Brisbane, Not Specified, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Part A: Dose Escalation Multiple doses of INX-315 monotherapy, oral administration	DRUG: INX-315 Oral administration
EXPERIMENTAL: Part B: Ovarian Dose Expansion INX-315 monotherapy, oral administration	DRUG: INX-315 Oral administration
EXPERIMENTAL: Part C: ER+/HER2- BC Dose Expansion INX-315 in combination with CDK4/6i and endocrine therapy, oral administration	DRUG: INX-315 Oral administration
EXPERIMENTAL: Part A INX-315 + Fulvestrant INX-315 dose plus Fulvestrant 500mg	DRUG: INX-315 Oral administration

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Part A and B: Evaluate the incidents of treatment emergent adverse events and laboratory abnormalities	Not Specified	Up to 12 months
Part A: Evaluate the occurrence of dose-limiting toxicities (DLTs) during Cycle 1	Not Specified	28 days
Part A: Recommend at least two doses of INX-315 to be evaluated in the expansion phase	Not Specified	Up to 12 months
Part B: Overall response rate (ORR)	Not Specified	Up to 36 months
Part B: Selection of Recommended Phase 2 Dose (RP2D)	Not Specified	Up to 36 months

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Part A and B: Characterize the maximum plasma concentration (Cmax)	Not Specified	Cycle 1 Day 1 and Day 15
Part A and B: Characterize the time to maximum plasma concentration (Tmax)	Not Specified	Cycle 1 Day 1 and Day 15
Part A and B: Characterize the Area under the plasma concentration versus time curve from time 0 to the end of the dosing interval (AUC0-24h)	Not Specified	Cycle 1 Day 1 and Day 15
Part A and B: Characterize the terminal half-life (t1/2)	Not Specified	Cycle 1 Day 1 and Day 15
Part A and B: Characterize the oral clearance (CL/F)	Not Specified	Cycle 1 Day 1 and Day 15
Part A: Overall response rate (ORR)	Not Specified	Up to 36 months
Part A and B: Disease control rate (DCR)	Not Specified	Up to 36 months
Part A and B: Progression free survival (PFS)	Not Specified	Up to 36 months
Part A and B: Duration of response (DOR)	Not Specified	Up to 36 months
Part A and B: Time to progression (TTP)	Not Specified	Up to 36 months
Part A and B: Overall survival (OS)	Not Specified	Up to 36 months

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer